Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in 
Substance Use Disorder and/or HIV-related processes
notice number: not-da-20-018key dates release date: march 25, 2020 first available due date: june 05, 2020 expiration date: september 08, 2023pa-19-056: nih research project grant (parent r01 clinical trial not allowed) pa-19-091: nih research project grant (parent r01 basic experimental studies with humans required) pa-19-052: nih small research grant program (parent r03 clinical trial not allowed) pa-19-053: nih exploratory/developmental research grant program (parent r21 clinical trial not allowed) par-18-437: cutting-edge basic research awards (cebra) (r21-clinical trial optional) pa-18-591: administrative supplements to existing nih grants and cooperative agreements (parent admin supp - clinical trial optional)issued by national institute on drug abuse (nida)purposethe purpose of this notice is to inform potential applicants to the national institute on drug abuse (nida) of special interest in research examining the roles of biomolecular condensates (bmcs) or their regulators in processes relevant to substance use disorders (suds) and/or hiv infection, latency, or pathogenesis.backgroundbiomolecular condensates (bmcs) are diverse and dynamic subcellular domains formed by liquid-liquid phase transitions in which multivalent proteins, rnas, or proteins with intrinsically disordered regions (idrs) nucleate subcellular regions with a distinct liquid phase in aqueous solution. bmcs have previously unrecognized and important roles in a wide variety of biological processes including regulation of gene expression, organization of subcellular structures in the nucleus and cytosol, and clustering of neurotransmitter-containing synaptic vesicles and voltage gated calcium channels at the synapse. recent work indicates that multiple proteins implicated in neurodegeneration associated with pathological protein aggregation also participate in the formation of bmcs. there is emerging evidence that dendritic spines and synapses utilize bmcs in their formation and dynamics. additionally, there is a recently discovered role for bmcs in modulation of receptor kinase signaling at membranes.cns bmcs and substance use disorders.much remains to be learned about the role of bmcs and their regulators in cns functions including chromatin structure, gene expression, dendritic spine formation, synaptic function, neurodegeneration, regeneration, or subcellular localization of channels, receptors, or vesicles. addictive substances impact many of these processes and could influence cns functions in part via bmcs. although a role for bmcs in receptor kinase signal transduction at the plasma membrane has been established, it is not known whether bmcs influence gpcr signal transduction, bdnf receptor function, or the functions of other signal transduction pathways relevant to addictive substances.bmcs and hiv.there is much we do not know about bmcs in hiv biology. for example, it has recently been shown that vesicular stomatitis virus (vsv) exploits a nuclear bmc for efficient replication of the vsv rna genome, but it is not known if hiv uses a bmc for a similar purpose. despite the emerging role for bmcs in establishing and regulating chromatin structure in the nucleus, little is known about the potential involvement of bmcs in hiv/siv infection, the formation or maintenance of hiv latency or whether hiv latency could be strengthened or diminished by manipulation of nuclear bmcs. dysregulation of bmc-related processes also could be involved in the etiology of hiv-associated neurocognitive disorder (hand).research objectivesthe purpose of this nosi is to encourage the submission of research projects examining the roles of bmcs or their regulators in processes relevant to suds and/or hiv infection, latency, or pathogenesis.it is anticipated that compelling projects will require interdisciplinary collaborations between individuals with expertise in bmcs and with significant knowledge of substance use and suds and/or hiv infection, replication, latency, or pathogenesis. applicants are encouraged to establish such collaborations.it is anticipated that investigations into the role of bmcs in substance use or sud-relevant processes or hiv infection, replication, latency, or pathogenesis could uncover potentially novel mechanistic insights. in addition, work in this area may yield potentially new and unexpected targets that could be exploited to treat suds, hiv, or hiv-related pathological consequences.some examples of research projects appropriate for this nosi include, but are not limited to:sud-relevanthiv-relevantsud and hiv-relevantapplication and submission informationthis notice applies to due dates on or after june 5, 2019 and subsequent receipt dates through september 8, 2023.submit applications for this initiative using one of the following funding opportunity announcements (foas) or any reissues of these announcement through the expiration date of this noticepa-19-056: nih research project grant (parent r01 clinical trial not allowed) pa-19-091: nih research project grant (parent r01 basic experimental studies with humans required) pa-19-052: nih small research grant program (parent r03 clinical trial not allowed) pa-19-053: nih exploratory/developmental research grant program (parent r21 clinical trial not allowed) par-18-437: cutting-edge basic research awards (cebra) (r21-clinical trial optional) pa-18-591: administrative supplements to existing nih grants and cooperative agreements (parent admin supp - clinical trial optional)all instructions in the sf424 (r&r) application guide and the funding opportunity announcement used for submission must be followed, with the following additions:inquiriesscientific/research contact(s)john satterlee, ph.d. national institute on drug abuse (nida) telephone: (301) 435-1020 email: satterleej@nida.nih.govpeer review contact(s)examine your era commons account for review assignment and contact information (information appears two weeks after the submission due date).financial/grants management contact(s)aida vasquez national institute on drug abuse (nida) telephone: 301-480-2154 email: vasquez@mail.nih.gov weekly toc for this announcement nih funding opportunities and noticesnote: for help accessing pdf, rtf, ms word, excel, powerpoint, audio or video files, see help downloading files.